Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 4/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10040061 | 0.96 | TDP1 (0.38) | TDP1TLR2CTSLCTSBCTSK | |
| SCHEMBL9945504 | 0.93 | TDP1 (0.49) | TDP1TLR2CTSLCTSBCTSK | |
| SCHEMBL19386614 | 0.89 | TDP1 (0.45) | TDP1 | |
| SCHEMBL16664682 | 0.85 | TDP1 (0.33) | TDP1 | |
| SCHEMBL9945511 | 0.84 | TP53 (0.33) | CTSLCTSBCTSK | |
| SCHEMBL487272 | 0.79 | TDP1 (0.47) | TDP1KDM4EUSP2ALDH1A1ALOX15 | |
| SCHEMBL895988 | 0.79 | TDP1 (0.47) | TDP1KDM4EUSP2ALDH1A1ALOX15 | |
| SCHEMBL503413 | 0.78 | TDP1 (0.44) | TDP1TLR2KDM4EUSP2ALDH1A1 | |
| SCHEMBL887703 | 0.78 | TDP1 (0.44) | TDP1TLR2KDM4EUSP2ALDH1A1 | |
| SCHEMBL11111869 | 0.78 | TDP1 (0.44) | TDP1TLR2KDM4EUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771466-B2 | Glycol ether-based cyclohexanoate ester plasticizers and blends therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771466-B2 | Glycol ether-based cyclohexanoate ester plasticizers and blends therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9228147-B2 | Glycol ether-based cyclohexanoate esters, their synthesis and methods of use | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-9228147-B2 | Glycol ether-based cyclohexanoate esters, their synthesis and methods of use | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150112008-A1 | Glycol Ether-Based Cyclohexanoate Ester Plasticizers and Blends Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2015-04-23 | — | — | US | disclosed |
| US-20150112008-A1 | Glycol Ether-Based Cyclohexanoate Ester Plasticizers and Blends Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2012082826-A1 | GLYCOL ETHER-BASED CYCLOHEXANOATE ESTERS, THEIR SYNTHESIS AND METHODS OF USE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120149620-A1 | GLYCOL ETHER-BASED CYCLOHEXANOATE ESTERS, THEIR SYNTHESIS AND METHODS OF USE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149620-A1 | GLYCOL ETHER-BASED CYCLOHEXANOATE ESTERS, THEIR SYNTHESIS AND METHODS OF USE | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149620-A1 | GLYCOL ETHER-BASED CYCLOHEXANOATE ESTERS, THEIR SYNTHESIS AND METHODS OF USE | GNE, UGT8, GK | TDP1 878/4885TLR2 2709/4885CTSL 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.